Fixed-Dose vs Adjustable-Dose Pen Injectors: Choosing by Therapy, Not by Feature List
Published 2026-10-27 · Keywords: fixed dose autoinjector
The fixed-versus-adjustable choice is made by the therapy’s dose schedule, not by the feature matrix. Fixed-dose suits one-dose-per-patient therapies; adjustable-dose suits titrated ones. Choosing wrong shows up late — as a human-factors problem on one side or a formulation constraint on the other — so it pays to make the decision from the dosing table first.
The decision table
| Your therapy profile | Device type | NOVIXPEN platform examples |
|---|---|---|
| One dose per patient per prescription; volume set by the fill | Fixed-dose autoinjector | WH-DF prefilled syringe platform (0.2–1.0 mL / 0.2–2.25 mL) |
| Titrated schedule — dose escalates over weeks | Adjustable-dose | WH-DG multi-dose (0.01 mL min, configs 37/74, 60, 80, 50) |
| Chronic, many doses per patient, cartridge replacement expected | Reusable adjustable | WH-RG (5 mL cartridge), A-60 (1–60 IU) |
| Emergency, single fixed dose, intramuscular | Fixed-dose emergency | UrgoPen (fill 0.15–2.0 mL, max 2.0 mL) |
| Two-component drug (lyophilized + diluent) | Dual-chamber reusable | 4 mL dual-chamber pen (0.01–0.5 mL, 0.01 mL steps) |
What each choice costs you
Fixed-dose simplifies everything downstream: one activation, no dial, the shortest training and human-factors story, and a device that is the natural consumable. What it costs is flexibility — the dose is the fill, so every dose strength is effectively a SKU, and titration is impossible.
Adjustable buys dose flexibility and fewer SKUs at the price of mechanics: a dose-setting mechanism, a dose window, and user steps that your human-factors file must cover. It also inherits an interface question — adjustable pens mostly take cartridges, which means the cartridge becomes a qualification item (see compatibility verification).
A frequent planning error: choosing adjustable “for flexibility” on a therapy whose label will never titrate. The flexibility is real but unused, and it costs mechanism complexity, dial-related usability evidence, and unit price.
How to verify the match
Bring the dosing table — every dose strength in the label and the target titration steps — to the device conversation. The platform either covers the table with its dose range and increments, or it does not; the A-75 covering 1–75 IU in 1 IU steps is coverable, a fixed-dose 1.0 mL PFS is not. Ask the supplier to map your table onto their platform configurations in writing.
What this does not cover
The devices ship empty and contain no drug; drug names here are dosing-schedule examples, not therapeutic claims. Dose strengths and titration schedules are decided by your clinical and regulatory teams.
Next step: send your dosing table and container format — we return the platform match with the configuration named, within one working day. Start the inquiry.
Related reading
Talk to NOVIXPEN about your program
Send your container format, annual volume and target market — we reply with the platform match, documentation set and written quotation within one working day.
Start the inquiry